Hexarelin
- Category
- Growth Hormone
- Administration routes
- Injectable
- Regulatory status
- Not FDA-approved
What it is
A synthetic growth hormone secretagogue, the most potent of its class, used for muscle growth, recovery, and a claimed heart-protective effect. It reliably triggers a growth hormone surge in humans, but the heart, anti-fibrotic, and lipid benefits rest mainly on animal and mechanism-only studies. A known drawback is fast tolerance, plus prolactin and cortisol effects. It is not FDA-approved and is sold mostly as unregulated research product.
Read Full recordStudied uses & evidence
Studied uses(6)
Potent growth hormone release
HighMultiple human studies confirm dose-dependent growth hormone release, exceeding GHRH in direct comparison.
Cardioprotection and improved cardiac function
MediumSmall human studies, including controlled comparisons, show acute cardiac function improvement in some but not all conditions.
Anti-fibrotic cardiac effects
LowReduced cardiac fibrosis in rodent and cell studies only; no human data available.
Evidence limits
- Evidence Level
- Phase II — Moderate
Hexarelin reached Phase II clinical trials for GH deficiency and congestive heart failure. Human studies (total ~50 subjects across multiple trials) demonstrate consistent GH release and acute cardioprotective effects. However, development was discontinued before Phase III, tolerance development limits chronic use, and the compound was never marketed. Preclinical evidence for cardioprotection is robust, but translational human data remains limited.
Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Cautions & risk summary
Do not use if
Active cancer
HighGH secretagogue — sustained GH/IGF-1 elevation promotes tumor growth.
Diabetic retinopathy
HighGH/IGF-1 elevation can worsen proliferative retinopathy.
Cardiovascular disease (severe)
ModerateHexarelin has direct cardiac effects via CD36 receptors. Use caution with existing heart conditions.
Diabetes/insulin resistance
ModerateGH elevation can impair glucose tolerance and worsen insulin resistance.
Risk summary(7)
Risks = level of concern: High · Moderate · Low · Theoretical
Unapproved compound
HighLimited long-term human safety data
HighHPA axis stimulation
ModerateProlactin elevation
ModerateTolerance development
ModeratePotential IGF-1 elevation concerns
TheoreticalWater retention and joint discomfort
Theoretical
Further reading
- Overview in Full record
- Safety & interactions in Full record
- Research & benefits in Full record
- Regulation & availability in Full record
- Sources in Full record
- Frequently asked questions in Full record
This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer
Compiled from published research indexed through March 2026.